NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program, where he discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola.
For business and technology leaders, this coverage signals growing interest in broad-spectrum antiviral approaches that could address multiple viral threats simultaneously. NV-387 is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company also has NV-CoV-2 (API NV-387) for COVID-19 and NV-CoV-2-R, which encapsulates remdesivir. The ability to tackle diverse viruses with a single platform could reduce development costs and time-to-market, potentially reshaping the antiviral landscape.
The FDA’s Orphan Drug Designation and Rare Pediatric Disease Designation filing for measles underscore the regulatory progress. The resurgence of measles, mpox, and Ebola highlights the ongoing need for novel antivirals. Leaders should note that NanoViricides is advancing NV-387 into Phase II human clinical trials, though the company cannot project exact IND filing dates due to reliance on external collaborators.
The analyst report’s price target of $6.00 suggests significant upside from current levels, reflecting confidence in the technology and pipeline. However, as with any drug development, there are risks: the path to typical drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any candidate will show sufficient effectiveness and safety for human clinical development.
NanoViricides’ platform technology is based on the TheraCour nanomedicine technology, licensed exclusively for specific human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes, Influenza, Dengue, Ebola, and certain Coronaviruses. The company also intends to obtain licenses for RSV, Poxviruses, and Enteroviruses if initial research is successful.
For investors and industry observers, the initiation of coverage by a reputable analyst provides additional visibility into the company’s potential. The full details of the analyst report and the fireside chat are available in the company’s newsroom at https://ibn.fm/NNVC. More information about NanoViricides can be found at www.nanoviricides.com.
